Halozyme Therapeutics (HALO) Stock: Buy, Sell, or Hold?
HALO - Halozyme Therapeutics, Inc.
$107.20
0.20 (0.19%)
â˛
5d:
-3.21%
30d:
+5.31%
90d:
+51.56%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 02, 2026
Get Alerted When HALO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: HALO is fairly priced but lacks strong directional signals. At 9.0% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: HALO is fairly priced but lacks strong directional signals. At 9.0% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$149.40
Based on 12.6% avg growth
INTRINSIC VALUE TODAY
$92.77
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HALO is currently trading at $107.20, which is considered slightly high relative to its 30-day fair value range of $94.49 to $111.15. From a valuation perspective, the stock is trading at a premium (Forward PE: 10.3) compared to its historical average (8.0). At these levels, the market is pricing in 9.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, HALO is in a strong uptrend. Immediate support is located at $103.47, while resistance sits at $111.15.
Market Sentiment: HALO scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HALO is in a strong uptrend. Immediate support is located at $103.47, while resistance sits at $111.15.
Market Sentiment: HALO scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$94.49 -
$111.15
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
34.8%
Protect Your Profits
Holding HALO? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Trading above Wall St target ($99.56)
- NEUTRAL: Trading at premium valuation - market expects 9.0% growth which is achievable
- WARNING: Composite score 48/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$94.49 -
$111.15
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$103.47
Resistance Level
$111.15
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.31
Wall Street Target
$99.56
(-7.1%)
Revenue Growth (YoY)
47.7%
Earnings Growth (YoY)
42.9%
Profit Margin
24.9%
Valuation Premium vs History
+9.0% premium
PE vs Historical
10.3 vs 8.0
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+9.0%
(market-implied from PE analysis)
1-Year Target
$116.85
(+9%)
2-Year Target
$127.36
(+19%)
3-Year Target
$138.83
(+30%)
3-Yr Target (if PE normalizes)
(PE: 10â8)
PE COMPRESSION
$107.67
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 21.2%)
$372.99
(+248%)
Base:
(SPY PE: 10.3, Growth: 21.2%)
$190.74
(+78%)
Bear:
(PE: 8.0, Growth: 21.2%)
$147.94
(+38%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (31x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 31.47 | Current EPS (TTM): $3.40
Bull Case
$235.40
(+120%)
Analyst growth 100.0%, PE expands to 34.6
Base Case
$214.00
(+100%)
Market implied 100.0%, PE stable at 31.5
Bear Case
$72.76
(-32%)
Severe decline -20.0%, PE contracts to 26.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 11, 2026 9:20 PM ET
Data refreshes hourly during market hours. Next update: 10:20 PM
Data refreshes hourly during market hours. Next update: 10:20 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HALO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Helen Torley
SELL
10000 shares
2026-04-06
Helen Torley
SELL
20000 shares
2026-04-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
Advanced HALO Option Strategies
Professional options setups generated by AI based on today's HALO price and gamma walls.
